November 2025 FDA Recall Famotidine by Fresenius Kabi Usa, Llc
D-0182-2026 - Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

This Class I drug recall was voluntarily initiated by Fresenius Kabi Usa, Llc on November 6, 2025 for the product Famotidine. The FDA reported the reason for recall as microbial contamination of sterile products; out of limit results obtained for endotoxin testing.. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0182-2026

Reason for Recall
Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Initiated
11-06-2025
Reported
12-03-2025
Quantity
2,199,850 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Fresenius Kabi USA, LLC
Nationwide within the United States as well as AK, HI, and PR.
Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL vials, Rx only, Fresenius Kabi USA, LLC, NDC 63323-739-11 (unit of use), 63323-739-12 (unit of sale).

Batch or Lot Expiration Information

Lot# : 6133156, 6133194, Exp Date: 08/2026; 6133388, Exp Date: 10/2026.

Affected Packages Involved in this Recall